Skip to main content

Table 1 The Socio-demographic and baseline characteristics in IPT and non IPT cohorts in Dilla University Referral Hospital

From: Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study

Baseline covariates

Non IPT cohort

IPT cohort

Total

N = 1548

N = 374

N = 1922

No. (%)

No. (%)

No. (%)

Gender

Female

848 (54.8)

225 (11.768.2)

1073 (55.8)

Age group

15 – 25 years

333 (21.5)

78 (20.9)

411 (21.4)

26 – 29 years

238 (15.4)

63 (16.8)

301 (15.7)

30 – 34 years

355 (22.9)

94 (25.1)

449 (23.4)

35 – 39 years

268 (17.3)

58 (15.5)

326 (17.0)

40 – 99 years

354 (22.9)

81 (21.7)

435 (22.6)

ART at baseline

No

1307 (84.4)

328 (87.7)

1635 (85.1)

Yes

241 (15.6)

46 (12.3)

287 (14.9)

Cotrimoxazole (ever use)*

Yes

1290 (83.3)

341 (91.2)

1631 (84.9)

WHO stage of HIV disease*

Stage I

141 (9.1)

39 (10.4)

180 (9.4)

Stage II

247 (16.0)

78 (20.9)

325 (16.9)

Stage III

1000 (64.6)

236 (63.1)

1236 (64.3)

Stage IV

160 (10.3)

21 (5.6)

181 (9.4)

WHO functional status*

Ambulatory

590 (38.1)

110 (29.4)

700 (36.4)

Bedridden

99 (6.4)

8 (2.1)

107 (5.6)

Working

859 (55.5)

256 (68.4)

1115 (58.0)

CD4*

0 – 99 cells/mm3

477 (30.8)

76 (20.3)

553 (28.8)

100 – 199 cells/mm3

561 (36.3)

142 (38.0)

703 (36.6)

200 - 349 cells/mm3

446 (28.8)

145 (38.8)

591 (30.8)

350 + cells/mm3

63 (4.1)

11 (2.9)

74 (3.9)

Body weight

< = 50 Kgs.

726 (47.5)

153 (41.6)

879 (46.4)

50-74 Kgs.

763 (50.0)

204 (55.4)

967 (51.0)

75 + Kgs.

38 (2.5)

11 (3.0)

49 (2.6)

Transfer in

yes

160 (10.3)

36 (9.6)

196 (10.2)

Point of entry to care (Entry from)

Referred from the same hospital

1197 (77.3)

296 (79.1)

1493 (77.7)

Self-referred

29 (1.9)

6 (1.6)

35 (1.8)

Referred from other health facilities

322 (20.8)

72 (19.3)

394 (20.5)

Outcomes

Censored

1301 (84.0)

363 (97.1)

1664 (86.6)

TB

105 (6.8)

5 (1.3)

110 (5.7)

Death

142 (9.2)

6 (1.6)

148 (7.7)

Composite outcome

TB or death

247 (16.0)

11 (2.9)

258 (13.4)

  1. *:p value < 0.05. ART Antiretroviral therapy, HIV Human Immunodeficiency Virus, IPT Isoniazid Preventive Therapy, N Number of people, TB Tuberculosis, and WHO World Health Organization